Luke Awtry From left: Sarah Vandal; Katie Queen; Hannah Poquette; Katie Schutt, PhD; Alex Thompson; Jason Stumpff, PhD; Carolyn Marquis; Leslie Sepaniac; and Cindy Fonseca, MS Significant advances in the fight against cancer aren t always made by a single inspired scientist; often they re accomplished by a team. The University of Vermont Cancer Center excels at supporting and promoting team science. Sometimes, those teams even include undergraduate students at UVM. During their time at Groovy UV, alumnae Lisa Wood, 18, and Carolyn Marquis, 19, contributed to foundational scientific research that could someday lead to new ways of fighting triple negative breast cancer. Both worked in a molecular physiology and biophysics lab run by UVM Larner College of Medicine associate professor Dr. Jason Stumpff. He s one of more than 210 members of the
Related Company:
Larner College of Medicine faculty Gary and Janet Stein are principal investigators on a new $9 million grant from the National Cancer Institute to explore the epigenetics of breast cancer with the goal of finding new drug targets. (Photos: Sally McCay, Larner College of Medicine)
Project to Identify New Targets for Drug Treatment That Could Prevent or Halt Disease
Vermont Business Magazine A team of University of Vermont scientists and physician investigators at the UVM Cancer Center and the Northern New England Clinical and Translational Research Network has been awarded a $9 million, five-year grant from the National Cancer Institute (NCI) to investigate the underlying causes of breast cancer with the goal of identifying new cellular-level targets that could be treated with drugs to prevent the disease or halt its progression.
The theses projects of two former undergrads, Lisa Wood (left) and Carolyn Marquis (right), were important contributors to new research that holds promising discoveries in the fight against cancer. Wood and Marquis pursued this work in the lab of the study’s lead author and UVM Cancer Center researcher Jason Stumpff. At center is a triple negative breast cancer cell, used to demonstrate a vulnerability that could be a potential target for interrupting cancer cell growth. (Photos: Courtesy of Lisa Wood, Cindy Fonseca and Carolyn Marquis)
When the University of Vermont announced last week that Professor Jason Stumpff’s molecular physiology and biophysics lab had made a discovery that could lead to new treatments for hard-to-treat cancers, two UVM alumnae took special satisfaction from the news. Lisa Wood 18, now a PhD student at the University of Colorado Anschutz School of Medicine, and Carolyn Marquis 19, who continues her work at the Stumpff lab, each made significant c
E-Mail
Unravelling the unique characteristics of cancer cells and finding less-harmful ways to stop their growth have long been a focus for cancer researchers worldwide. New findings, reported in
Nature Communications, describe the discovery of a unique dependence of cancer cells on a particular protein, which could lead to desperately needed treatment for hard-to-treat cancers.
The publication caps off a series of groundbreaking studies appearing in Nature journals over the last month by members of a powerful international research collaboration.
Lead author and University of Vermont (UVM) Cancer Center researcher Jason Stumpff, Ph.D., has spent over two decades studying how cells divide and how mistakes in this process contribute to diseases, such as cancer. His recent work has enhanced understanding of the role of a protein called KIF18A in driving cell division. In these new studies, Stumpff s lab demonstrates that cancer cells, with the type of abnormalities seen in agg
Cancer cell vulnerability could be a potential target for interrupting tumor growth news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.